bioAffinity Technologies' CEO, Maria Zannes, will lead a panel of leaders from UT Health, UTSA and the City of San Antonio to discuss how the Company has grown in San Antonio and how others can benefit from their story. Thursday, November 9 at noon at the San Antonio Airport Hilton.
read moreTexas Public Radio (August 24, 2017 ) A new, more accurate, test for lung cancer is being developed in San Antonio. It’s a screening that could help save the lives of thousands of people who are often diagnosed too late to survive the disease.
read moreSan Antonio Express-News (July 27, 2017) San Antonio-based biotech company bioAffinity raised over $4 million as it plans to bring its new lung cancer test to market next year, according to securities filings.
read moreOnline registration is now open and the RSVP deadline is Fri. May 19th. ACG Member price: $30./Non-ACG Member price: $55. until the RSVP deadline.
read moreSAN ANTONIO, TX (May 3, 2017) bioAffinity Technologies announced that the European Patent Office (EPO) has issued a patent that protects the Company’s proprietary CyPath® technology for the early detection of lung cancer through 2030.
read more